1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
RPG Life Sciences Limited

RPG Life Sciences Limited

2,638.85
INR
-129.60
(-4.68%)
65.96EPS
34.93P/E
38.11BMarket Cap
RPG Life Sciences Limited
BSE:RPGLIFE
(Bombay Stock Exchange)

Recent

price

2,638.85

P/E

ratio

34.93

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
112.99
116.61
134.04
142.45
146.25
168.67
174.06
203.85
195.85
223.2
231.81
264.32
307.81
349.16
391.52
424.45
436.3
Revenue per Share
7.69
0.51
2.67
32.29
0.6
7.03
12.7
8.13
6.54
17.54
24.19
31.13
40.9
53
110.79
69.64
65.96
Basic EPS, GAAP
1.9
4.2
-0.17
-11.62
-7.68
19.84
4.43
-0.48
15.78
23.84
30.09
24.67
35.12
15.19
25.29
-5.36
- -
Free Cash Flow per Basic Share
1.29
1.58
0.79
1.18
2.31
2.87
0.15
3.34
2.9
7.72
- -
7.2
9.6
12
16
24
- -
Dividend per Share
45.25
44.84
46.1
76.06
75.69
76.56
88.89
93.57
97.04
106.76
130.87
154.65
185.98
226.65
320.77
366.01
- -
Book Value per Share
30.93
32.05
33.95
64.59
64.85
66.66
55.95
60.44
65.49
81.44
108.42
133.68
165.79
209.7
307.01
361.11
- -
Tangible Book Value per Share
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Basic Weighted Avg Shares
1,868
1,928
2,216
2,356
2,418
2,789
2,879
3,372
3,239
3,692
3,834
4,372
5,091
5,775
6,475
7,020
7,215
Sales/Revenue/Turnover
12.71
4.46
3.21
0.53
2.17
5.2
6.24
7.77
5.92
11.98
14.27
16.41
17.46
19.41
21.68
18.05
17.91
Operating Margin (%)
95
102
99
106
114
102
118
143
153
164
165
157
155
171
214
215
222
Depreciation Expense
127
9
44
534
10
116
210
135
108
290
400
515
676
877
1,832
1,152
1,091
Net Income, GAAP
27.25
51.15
- -
17.81
- -
- -
16.85
33.94
28.17
20.41
25.35
29.64
26.22
25.61
21.32
25.31
25.39
Effective Tax Rate (%)
6.8
0.44
1.99
22.67
0.41
4.17
7.3
3.99
3.34
7.86
10.43
11.78
13.29
15.18
28.3
16.41
15.12
Profit Margin (%)
-25
-31
-124
203
189
101
177
219
193
432
962
1,268
1,613
1,671
3,454
3,989
- -
Working Capital
248
207
105
4
3
3
161
102
66
15
7
3
- -
- -
- -
133
- -
LT Debt
748
741
762
1,258
1,252
1,266
1,470
1,548
1,605
1,766
2,165
2,558
3,076
3,749
5,305
6,054
- -
Total Equity
16.22
3.69
- -
40.77
2.03
8.86
8.81
8.26
6.79
16.01
20.12
21.28
23.12
24.53
39.12
17.97
- -
Return on Invested Capital (%)
16.22
3.69
- -
42.11
2.5
9.17
13.56
7.97
6.74
15.78
19.96
21.82
24.05
25.79
40.59
20.04
- -
Return on Capital (%)
18.25
1.14
5.87
52.87
0.8
9.23
15.36
8.91
6.86
17.21
20.36
21.8
24.01
25.69
40.48
20.28
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
67
- -
LT Borrowings
- -
133
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
38,379
30,600
38,109

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
5,595
- -
Cash, Cash Equivalents & STI
- -
2,744
- -
Accounts Receivable, Net
- -
1,167
- -
Inventories
- -
1,238
- -
Total Current Liabilities
- -
1,606
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
67
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.36%
23.18%
14.1%
Free Cash Flow
-356.09%
-17.42%
-121.18%
Net Income, GAAP
39.3%
32.31%
-37.15%
Sales/Revenue/Turnover
9.87%
12.89%
8.41%
Total Cash Common Dividend
- -
- -
50%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,654
1,722
1,727
1,431
6,475
2026
1,689
- -
1,800
1,769
7,020
2027
1,957
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.18
2.54
21.12
70.96
110.79
2026
15.9
- -
13.38
18.08
69.64
2027
18.6
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
16
2026
- -
- -
- -
- -
24
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
RPG Life Sciences Limited (RPGLIFE.NS), a subsidiary of RPG Enterprises headquartered in Mumbai, India, manufactures and markets branded formulations, global generics and synthetic active pharmaceutical ingredients (APIs) across domestic and international markets including Europe, Latin America, Australia, Southeast Asia and over 50 countries worldwide; the company operates in more than 10-13 therapeutic areas such as nephrology, oncology, urology, respiratory, cardiology, diabetology, rheumatology, gastroenterology, anti-infectives and immunosuppressants, featuring well-known brands including Aldactone (spironolactone), Serenace (haloperidol), Naprosyn (naproxen) and Azoran (azathioprine); its production facilities include formulations plants in Ankleshwar, Gujarat and a synthetic API facility in Navi Mumbai, both compliant with EU, TGA, Canada, Japan and Australian standards. Originally founded in 1968 as Searle India Ltd through a joint venture with GD Searle USA and renamed RPG Life Sciences in 1999 after acquisition by RPG Group in 1993, the company maintains a research-driven focus on quality affordable medicines with ongoing R&D investment in formulation development, monoclonal antibodies and biosimilars. In recent developments, RPG Life Sciences pursues strategic acquisitions across APIs, formulations and emerging therapies bolstered by a cash surplus exceeding Rs 223 crore and zero debt following Thane land monetization and debt clearance; it eyes value-accretive deals under new Managing Director Ashok Nair appointed in May 2025 while advancing its five-pillar growth strategy encompassing mega brands like Naprosyn targeting Rs 100 crore sales, immunosuppressant expansion to Rs 100 crore domestic and Rs 200 crore global, monoclonal antibody launches in rheumatology/nephrology, international operations scaling including Canadian OTC approval for Naprosyn, API plant recovery post-fire by November 2025 and capex investments of Rs 140-150 crore in facility modernizations; FY25 revenue reached Rs 582.1 crore up 13.5% with EBITDA margin at 22.2%.